The vaccine rollout is a critical step toward restoring normalcy of the world. The vaccine was developed by a small group of countries that chose to patent it. Hence, the production and distribution remained in the hands of a few countries, resulting in significant disparities in the global rollout. COVID-19 knows no national borders nor does it discriminate anyone based on migration status. However, the COVID-19 affected disproportionately the racial minorities and the migrant population. Pandemics are global health crises. As a result, proposals for a patent waiver for the COVID-19 vaccine may benefit countries in obtaining the vaccine. Unfortunately, regardless of how severe the situation is, therapeutic and preventive measures like vaccine development, marketing, and distribution have been politicized as a result of hegemonic ambition. Both producing and import-dependent countries are vying for diplomatic victory: the former must win to gain hegemony, while the latter must win to obtain the vaccine. As a result, migrant workers are less likely to receive their immunization in a timely manner. This article engages in the decades-long debate over intellectual property rights and patenting life-saving vaccines. I contend that exemption of COVID-19 vaccines from intellectual property rights would promote global access and equity.